Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## VENTUREPHARM LABORATORIES LIMITED

## 萬全科技藥業有限公司\*

(incorporated in the Cayman Islands with limited liability)
(Stock Code: 8225)

## INDICATIVE ANNOUNCEMENT

The Board of directors( [the "Board"]) of Venturepharm Laboratories Limited ( [the "Company"]) hereby inform the shareholders of the Company and the potential investors that because of the accounting treatment of Convertible Bonds, going concern assessment, impairment of receivables and impairment of Work-in-progress which caused the delay of the auditing work of the year 2011, and as a result, the audited annual results of the year 2012 is expected to be completed and released before 30 April, 2013. At the request of the Company, trading in the securities of the Company on the Stock Exchange has been suspended from 9:00 a.m. on 2 April, 2012, and will remain suspended until the release of an announcement relating to the publication of its annual results for the year 2012.

Save as disclosed above, the Company is not aware of any other matters that need to be brought to the attention of the shareholders and potential investors of the company.

By order of the Board

Venturepharm Laboratories Limited

William Xia Guo

Chairman

## \* For identification purpose only

As at the date of this announcement, the Board comprises two executive directors, being Mr. William Xia Guo and Dr. Maria Xue Mei Song; three non-executive directors, being Mr. Feng Tao, Dr. Nathan Xin Zhang and Mr. Li Jin Liang; and three independent non-executive directors, being Mr. Zhang Jing An, Mr. Paul Contomichalos and Mr. Wu Shou Yuan.

This announcement, for which the directors of the Company (the "Directors") collectively and individually accept responsibility, includes particulars given in compliance with the Rules Governing the Listing of securities of the Growth Enterprise Market of the Stock Exchange for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, conform that, to the best of their knowledge and belief: (1) the information contained in this announcement is accurate and complete in all material respect and not misleading; (2) there are no other matters the omission of which would make any statement in all material respects and not misleading; and (3) all opinions expressed in this announcement have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.

This announcement will remain on the GEM website with the domain name of www.hkgem.com on the "Latest Company Announcements" page for at least 7days from the date of its posting and on the Company's website at www.venturepharm.com